Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Apr;84(4):551-5.
doi: 10.4269/ajtmh.2011.10-0423.

Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis

Tracey Newlove  1 , Luiz H Guimarães, Daniel J Morgan, Leda Alcântara, Marshall J Glesby, Edgar M Carvalho, Paulo R Machado
Affiliations
Randomized Controlled Trial

Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis

Tracey Newlove et al. Am J Trop Med Hyg. 2011 Apr.

Abstract

Helminth infections influence the clinical response to certain diseases and are associated with delayed healing time of patients with cutaneous leishmaniasis (CL) caused by Leishmania braziliensis. We conducted a randomized, double-blind, placebo-controlled clinical trial to examine the role of early versus deferred treatment of intestinal helminth infection on the clinical course of patients with CL treated with pentavalent antimony. (Clinicaltrials.gov number NCT00469495). A total of 90 patients were enrolled, 51.1% (N = 23) of control patients had persistent lesions at Day 90, compared with 62.2% (N = 28) in the treatment group (difference 11.1%, 95% confidence interval = -9.1-30.0%). There was no statistically significant difference in overall time to cure between groups, although there was a tendency for shorter cure times in the control group. This study shows that early introduction of antihelminthic therapy does not improve clinical outcome in patients co-infected with helminths and L. braziliensis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagramatic representation of the study design.
Figure 2.
Figure 2.
Lesion healing in patients with cutaneous leishmaniasis (CL), stratified by group assignment; P = 0.13 log-rank test.
See this image and copyright information in PMC

References

    1. Jones T, Johnson W, Barretto A, Lago E, Marsden P. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis. J Infect Dis. 1987;156:73–83. - PubMed
    1. Correia D, Macêdo V, Carvalho E, Barral A, Magalhães A, Abreu M, Orge M, Marsden P. Comparative study of meglumine antimonate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Vianna) braziliensis. Revista da Sociedade Brasiliera de Medicina Tropical. 1996;29:447–453. - PubMed
    1. Romero G, Guerra M, Paes M, Macedo V. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg. 2001;65:456–465. - PubMed
    1. Bacellar O, Lessa H, Schriefer A, Machado P, Jesus A, Dutra WO, Gollob KJ, Carvalho EM. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70:6734–6740. - PMC - PubMed
    1. Ribeiro-de-Jesus A, Almeida R, Lessa H, Bacellar O, Carvalho E. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998;31:143–148. - PubMed

Publication types

MeSH terms

Associated data